ESR1 (Estrogen Receptor 1) overexpression is observed in 60–70% of the human breast cancers, and the hyper-activation of the Estrogen signaling pathway provides proliferative advantages, as well as the metastatic potential to the cancer cells. This evidence concerns the gene ESR1 and breast carcinoma.